rna
virus
exhibit
increas
mutat
frequenc
rel
organ
recent
work
attempt
exploit
uniqu
featur
increas
viral
mutat
frequenc
beyond
extinct
threshold
antivir
strategi
known
lethal
mutagenesi
number
novel
nucleosid
analog
design
around
premis
herein
review
quasispeci
natur
rna
virus
survey
antivir
biolog
biochem
characterist
mutagen
nucleosid
analog
includ
clinicallyus
ribavirin
biolog
implic
modul
viral
replic
fidel
discuss
context
translat
lethal
mutagenesi
clinicallyus
antivir
strategi
replic
fidel
adapt
shown
affect
viral
spread
pathogenesi
result
viru
popul
less
abl
evolv
resist
classic
antivir
target
viral
enzym
structur
protein
thu
lethal
mutagenesi
may
effect
reduc
viral
load
may
also
result
select
viru
popul
reduc
pathogen
capac
resist
herein
review
progress
develop
lethal
mutagenesi
novel
antivir
strategi
eye
toward
futur
mileston
may
allow
effect
translat
strategi
clinic
set
rna
virus
display
extraordinarili
high
mutat
frequenc
compar
dnabas
organ
mutat
rate
rna
virus
gener
accept
rang
mutat
per
incorpor
nucleotid
compar
per
base
pair
dnabas
organ
result
approxim
one
mutat
per
genom
per
replic
cycl
rna
virus
mutat
per
genom
per
replic
cycl
retrovirus
equival
valu
dnabas
microb
per
genom
per
replic
cycl
even
though
genom
size
order
magnitud
larger
clearli
rna
virus
subject
extens
mutat
replic
phenomenon
like
due
absenc
proofread
activ
associ
viral
rnadepend
rna
polymeras
rdrp
enzym
respons
replic
rna
genom
although
recent
work
suggest
coronavirus
may
possess
proofread
activ
may
requir
rna
virus
genom
longer
nucleotid
extrem
high
mutat
rate
rna
virus
lead
gener
quasispeci
extrem
heterogen
popul
hover
around
mostfit
master
sequenc
individu
genom
popul
sequenc
differ
consensu
sequenc
one
nucleotid
chang
studi
chemic
mutagenesi
polioviru
pv
vesicular
stomat
viru
demonstr
upper
limit
increas
mutat
frequenc
rna
virus
mutat
frequenc
singl
site
could
increas
even
presenc
mutagen
suffici
reduct
viru
viabil
loeb
colleagu
util
retroviru
hiv
also
demonstr
signific
decreas
viru
viabil
mutat
frequenc
increas
modestli
serial
passag
hiv
presenc
mutagen
increas
mutat
rate
threefold
suffici
extinct
viru
popul
subsequ
loeb
mullin
coin
term
lethal
mutagenesi
describ
antivir
strategi
base
increas
viral
mutat
rate
level
beyond
popul
longer
genet
viabl
mechan
lethal
mutagenesi
illustr
typic
singlestrand
positivesens
rna
viru
figur
similarli
appli
rna
virus
replic
strategi
well
retrovirus
although
retrovir
mutat
must
occur
either
incorpor
mutagen
dna
revers
transcriptas
incorpor
viral
rna
cellular
rna
polymeras
ii
viral
rna
replic
follow
deliveri
genom
cytoplasm
product
necessari
viral
protein
includ
rdrp
replic
errorpron
result
gener
approxim
one
mutat
per
progeni
genom
left
panel
treatment
nucleosid
mutagen
allow
intracellular
accumul
mono
diand
triphosphoryl
form
triphosphori
late
analog
function
ambigu
substrat
rdrp
induc
addit
mutat
progeni
genom
result
deleteri
mutat
per
genom
therefor
lower
averag
fit
viral
popul
wherea
quasispeci
theori
invok
explain
antivir
activ
mutagen
theoret
underpin
quasispeci
theori
appli
evolut
viru
popul
still
quit
thin
subject
heat
debat
recent
interest
lethal
mutagenesi
antivir
strategi
stimul
effort
explain
scientif
theori
behind
lethal
mutagenesi
virologist
bull
sanjuan
wilk
describ
theori
lethal
mutagenesi
popul
genet
theori
show
extinct
threshold
depend
upon
mutat
rate
also
fecund
maxim
number
progeni
releas
therefor
measur
viral
fit
figur
experiment
support
concept
demonstr
footandmouth
diseas
viru
low
viral
load
low
fit
increas
frequenc
viral
extinct
thu
lethal
mutagenesi
genet
environment
compon
extinct
occur
mutat
rate
reduc
averag
viral
fit
point
popul
replenish
importantli
bull
sanjuan
wilk
note
distinct
genet
signatur
lethal
mutagenesi
differenti
mutagenesi
lead
lethal
led
difficulti
reconcil
theoret
breakthrough
empir
observ
viru
popul
subject
mutagen
agent
particularli
sinc
mutat
rate
fecund
difficult
paramet
accur
assess
vivo
addit
propos
defect
genom
may
function
lethal
defect
drive
viral
popul
extinct
lower
mutat
rate
import
concept
aris
look
rna
viru
popul
genet
idea
surviv
flattest
use
digit
organ
wilk
et
al
show
high
fit
popul
outcompet
lower
fit
popul
high
mutat
rate
lower
fit
popul
lie
flatter
region
fit
landscap
word
high
narrow
fit
peak
inferior
lower
broader
fit
plateau
mutat
fit
plateau
minim
effect
overal
fit
popul
owe
support
sequenc
similar
fit
connect
fit
landscap
surviv
flattest
lead
evolut
mutat
robust
popul
subject
high
error
rate
mutat
robust
refer
abil
popul
minim
effect
high
mutat
frequenc
favor
sequenc
resist
mutat
given
linear
increas
mutat
rate
result
exponenti
reduct
viral
fecund
figur
even
slight
increas
mutagenesi
may
suffici
drive
viral
popul
extinct
rna
virus
particularli
sensit
genet
meltdown
sinc
genom
extraordinarili
dens
inform
viral
genom
encod
protein
well
rna
structur
signal
translat
replic
small
size
result
numer
strategi
maxim
genet
inform
includ
transcript
slippag
program
ribosom
frameshift
number
allow
mutat
per
replic
cycl
therefor
rel
small
henc
rna
virus
like
exist
near
extinct
threshold
may
particularli
suscept
minor
increas
mutat
frequenc
crotti
et
al
use
pv
model
demonstr
experiment
small
chang
mutat
frequenc
result
rapid
reduct
viral
fecund
natur
pv
replic
result
approxim
mutat
per
genom
base
sequenc
ana
lysi
capsidcod
region
pv
grown
presenc
mutagen
dramat
declin
specif
infect
pv
genom
rna
seen
mutat
frequenc
exceed
two
mutat
per
genom
furthermor
approxim
fourfold
increas
mutat
rate
suffici
caus
reduct
specif
infect
observ
provid
addit
support
notion
small
increas
mutagenesi
necessari
allow
potent
antivir
effect
subsequ
work
demonstr
extinct
viru
popul
applic
chemic
mutagen
fmdv
driven
extinct
combin
mutagen
antivir
inhibtor
recent
work
shown
treatment
mutagen
alon
suffici
extinct
mutagen
nucleobas
caus
increas
mutat
frequenc
prototyp
arenaviru
lymphocyt
choriomening
viru
lcmv
abl
drive
viru
popul
extinct
aforement
experi
suggest
viral
quasispeci
might
repres
novel
antivir
target
exploit
current
antivir
agent
target
viral
protein
approach
instead
target
genet
inform
viral
polymeras
ultim
mediat
antivir
activ
lethal
mutagen
nucleosid
would
ideal
affect
polymeras
function
tradit
polymeras
inhibitor
chaintermin
nucleosid
instead
eventu
goal
would
develop
stealth
nucleosid
would
discrimin
viral
polymeras
would
corrupt
viral
genet
inform
incorpor
rna
genom
antivir
activ
ribavirin
ribavirin
synthet
purin
analog
first
report
figur
nucleosid
broadspectrum
antivir
activ
effect
cultur
cell
wide
rang
rna
dna
virus
clinic
use
combin
treatment
hcv
infect
monotherapi
treatment
lassa
fever
viru
respiratori
synciti
viru
herpesviru
infect
also
use
experiment
treatment
numer
virus
recent
sarsassoci
coronaviru
ribavirin
clinic
administ
nucleosid
upon
enter
cell
rapidli
convert
ribavirin
monophosph
rmp
cellular
adenosin
kinas
phosphori
lation
cellular
kinas
lead
accumul
ribavirin
triphosph
rtp
rtp
primari
form
ribavirin
found
treat
cell
although
rmp
also
present
level
lower
triphosph
ribavirin
exhibit
antivir
activ
wide
rang
dna
rna
virus
laboratori
mechan
action
remain
elus
review
year
antivir
activ
ribavirin
thought
due
inhibit
cellular
inosin
dehydrogenas
impdh
although
polymeras
inhibit
immun
modul
inhibit
cap
viral
rna
also
implic
potenti
mechan
recent
becom
appar
ribavirin
induc
transit
mutat
viral
genom
via
ambigu
basepair
subsequ
incorpor
viral
rdrp
crotti
colleagu
abl
demonstr
rtp
incorpor
pv
use
vitro
primerextens
assay
rmp
incorpor
approxim
rate
incorrect
nucleotid
opposit
either
cytidin
uridin
templat
contain
ribavirin
abl
direct
incorpor
cytidin
uridin
approxim
effici
promiscu
basepair
capac
presum
due
rotat
carboxamid
moieti
ribavirin
pseudobas
result
two
distinct
hydrogenbond
configur
figur
evid
implic
lethal
mutagenesi
mechan
action
ribavirin
subsequ
extend
viru
speci
includ
hcv
gb
viru
b
fmdv
west
nile
viru
hantaan
viru
howev
mechan
action
ribavirin
vivo
still
hotli
debat
thu
despit
extens
effort
understand
phenomenon
lethal
mutagenesi
vitro
littl
known
potenti
lethal
mutagenesi
bona
fide
clinic
antivir
strategi
broadspectrum
activ
ribavirin
unparallel
among
antivir
drug
led
consider
interest
develop
structur
analog
may
exhibit
increas
activ
greater
select
regard
host
cell
function
metabol
viramidin
figur
amin
prodrug
rapidli
convert
ribavirin
upon
absorpt
levovirin
lanalog
ribavirin
phosphoryl
vitro
lack
mutagen
antivir
activ
recent
moriyama
et
al
synthes
number
ribavirin
analog
contain
hydrophob
group
pyrazol
ring
nucleobas
modifi
ribavirin
two
analog
figur
c
demonstr
incorpor
rate
similar
ribavirin
pv
employ
within
threefold
opposit
either
natur
pyrimidin
antivir
activ
observ
basi
result
unclear
may
due
ineffici
intracellular
phosphoryl
reduc
mutagen
result
constrain
rotat
carboxamid
moieti
owe
steric
hindranc
substitut
adjac
novel
nucleosid
analog
could
improv
upon
antivir
activ
ribavirin
number
way
ribavirin
incorpor
slowli
viral
polymeras
rate
incorrect
nucleotid
nucleosid
effici
rate
incorpor
may
greater
antivir
effect
addit
nucleosid
differ
templat
properti
instanc
nucleosid
mimic
either
cytidin
uridin
could
exploit
lower
cellular
concentr
compet
pyrimidin
pyrimidin
analog
might
effect
administ
combin
purin
analog
ribavirin
allow
possibl
genom
site
target
novel
nucleosid
analog
may
also
possess
desir
properti
increas
cellular
phosphoryl
lead
rapid
accumul
target
cell
improv
discrimin
cellular
enzym
provid
greater
specif
antivir
respons
offtarget
cellular
effect
final
ribavirin
treatment
caus
signific
clinic
side
effect
owe
pleiotrop
biolog
properti
develop
nucleosid
analog
secondari
activ
might
elimin
undesir
effect
clinic
treatment
nucleosid
induc
mutagenesi
direct
incorpor
nucleic
acid
divid
two
gener
categori
depend
properti
attach
nucleobas
first
contain
nucleobas
minim
hydrogenbond
capac
incorpor
opposit
natur
occur
nucleosid
class
molecul
known
univers
base
second
categori
includ
nucleosid
contain
base
ambigu
hydrogenbond
properti
allow
favor
hydrogenbond
interact
two
natur
nucleobas
ribavirin
number
nonhydrogenbond
nucleosid
analog
develop
mostli
deoxyribonucleosid
gener
hydrophob
aromat
base
stabl
nucleic
acid
duplex
due
primarili
basestack
interact
interact
depend
upon
hydrogen
bond
base
show
littl
discrimin
pair
opposit
natur
occur
nucleobas
type
nucleosid
analog
shown
util
use
degener
primer
probe
unfortun
analog
gener
poor
substrat
enzym
one
univers
ribonucleosid
nucleosid
figur
synthes
investig
lethal
mutagen
pv
deoxyribonucleosid
contain
base
known
hybrid
four
base
dna
duplex
howev
exhibit
signific
antivir
effect
pv
primerextens
assay
use
pv
triphosphoryl
form
demonstr
nucleosid
fact
possess
mutagen
properti
incorpor
analog
either
adenosin
uridin
howev
exhibit
true
univers
characterist
incorpor
opposit
four
natur
base
significantli
incorpor
approxim
slower
ribavirin
vitro
therefor
incorpor
much
less
per
genom
replic
make
compound
ineffect
antivir
mutagen
overcom
shortcom
secondgener
analog
increas
aromat
system
enhanc
interact
design
nucleosid
figur
deoxyribonucleosid
contain
base
shown
increas
duplex
stabil
rel
effici
univers
substrat
dna
polymeras
although
demonstr
chaintermin
properti
triphosph
inde
found
templat
approxim
equal
well
four
natur
base
act
substrat
pv
rdrp
incorpor
tenfold
rapidli
triphosph
triphosph
still
tenfold
slower
ribavirin
pv
rdrp
incorpor
howev
chain
termin
observ
ribonucleosid
oppos
result
observ
deoxyribonucleosid
nucleotid
incorpor
slowli
effect
mutagen
prove
inhibitor
pv
polymeras
k
order
result
obtain
suggest
nonhydrogenbond
analog
may
effect
lethal
mutagen
hydrogenbond
interact
may
essenti
stabil
nucleosid
triphosph
substrat
activ
site
polymeras
order
allow
incorpor
nucleic
acid
biolog
relev
timescal
howev
particular
structur
nucleobas
may
uniqu
properti
prevent
effect
incorpor
rel
potenti
univers
base
furthermor
particular
polymeras
test
pv
may
less
effici
util
nonhydrogenbond
base
polymeras
virus
therefor
potenti
nonhydrogenbond
univers
base
function
lethal
mutagen
rule
current
avail
data
suggest
univers
nucleosid
may
poor
choic
mediat
viral
mutagenesi
second
major
class
mutagen
base
includ
exhibit
ambigu
hydrogenbond
properti
case
hydrogenbond
interact
present
uniqu
pattern
hydrogen
bond
donor
acceptor
display
depend
configur
molecul
hydrogenbond
pattern
vari
base
factor
rotat
ioniz
tautomer
base
moieti
ribavirin
exampl
class
molecul
rotat
exocycl
carboxamid
allow
nucleosid
mimic
either
natur
occur
purin
figur
similarli
figur
substitut
either
natur
occur
pyrimidin
furthermor
mutagen
activ
figur
hiv
like
due
increas
preval
imino
tautom
allow
effect
base
pair
adenosin
well
guanosin
investig
antivir
properti
exhibit
harki
et
al
synthes
seri
cytidin
ribonucleosid
analog
evalu
antivir
activ
rna
virus
pv
coxsackieviru
one
analog
particular
figur
exhibit
potent
antivir
activ
polymeras
inhibit
mechan
rather
mutagenesi
incorpor
nucleotid
nearli
slower
cytidin
ctp
research
koroni
pharmaceut
redmond
wa
usa
describ
novel
mutagen
deoxynucleosid
analog
figur
demonstr
potent
antivir
activ
hiv
vitro
relat
ribonucleosid
clinic
investig
oncolog
although
evalu
antivir
activ
publish
shown
inhibit
hiv
ec
nm
therapeut
index
tautomer
nucleobas
imino
amino
form
presum
allow
base
pair
either
natur
purin
figur
compound
increas
mutat
frequenc
provir
dna
evid
evolut
resist
genotox
host
prodrug
current
phase
iia
clinic
trial
monotherapi
treatment
infect
treatmentexperienc
patient
harbor
viru
signific
resist
standard
antiretrovir
trial
suspend
koroni
investig
discrep
preclin
vitro
data
examin
phase
iia
clinic
result
suspens
request
us
fda
due
safeti
concern
observ
drugrel
advers
event
figur
bicycl
pyrimidin
analog
mimic
either
cytidin
uridin
tautomer
nucleobas
compound
shown
induc
transit
mutat
escherichia
coli
vitro
retrovir
replic
model
pv
genom
synthes
vitro
contain
rp
demonstr
substanti
reduct
viral
fit
nucleotid
effici
promiscu
substrat
pv
spite
properti
rp
demonstr
antivir
activ
pv
cell
cultur
owe
insuffici
phosphoryl
cellular
kinas
prodrug
approach
may
ultim
prove
fruit
highlight
complex
design
nucleosid
analog
induc
mutagenesi
time
maintain
activ
substrat
critic
cellular
enzym
nucleosid
nucleotid
kinas
requir
convers
nucleosid
triphosh
tautomer
strategi
ambigu
basepair
advanc
synthesi
varieti
purin
nucleotid
analog
potent
analog
design
figur
c
respect
increas
mutat
frequenc
pv
singl
passag
result
reduct
viral
titer
similar
result
obtain
picornaviru
significantli
nucleosid
phosphoryl
intracellularli
yet
appear
substrat
cellular
ribonucleotid
reductas
suggest
potenti
host
genotox
may
minim
clearli
one
limit
factor
pharmaceut
exploit
lethal
mutagenesi
phenomenon
high
level
endogen
nucleosid
normallyfunct
cell
four
natur
ribonucleosid
found
intracellular
concentr
rang
hundr
micromolar
low
millimolar
target
retrovirus
deoxynucleosid
analog
overcom
issu
degre
dntp
found
much
lower
concentrationsapproxim
lower
anoth
primari
concern
induct
genom
mutat
host
cell
even
cell
bodi
infect
target
viru
deoxyribonucleosid
analog
clearli
potenti
genotox
ribonucleotid
may
also
incorpor
cellular
dna
convert
deoxyribonucleotid
cellular
ribonucleotid
reductas
substrat
specif
ribonucleotid
reductas
welldefin
design
analog
resist
convers
difficult
select
host
cell
mutat
achiev
owe
enhanc
proofread
activ
possess
cellular
replic
machineri
absent
viral
replicas
examin
nucleosid
pool
mammalian
cell
also
provid
direct
develop
antivir
nucleosid
intracellular
pyrimidin
concentr
gener
much
lower
purin
concentr
traut
compil
approxim
publish
valu
nucleosid
nucleotid
concentr
averag
concentr
atp
gtp
human
cell
thought
approxim
respect
concentr
pyrimidin
uridin
utp
ctp
approxim
respect
dispar
due
primarili
extrem
high
intracellular
concentr
atp
indic
essenti
role
energi
sourc
myriad
cellular
process
develop
pyrimidin
analog
thu
ensur
intracellular
competitor
minimum
potenti
requir
lower
drug
concentr
effect
addit
purin
intim
involv
essenti
cellular
chemistri
beyond
dna
rna
synthesi
necessari
divers
process
metabol
process
signal
translat
thu
focus
mutagen
pyrimidin
analog
may
result
fewer
advers
cellular
effect
one
potenti
complic
develop
mutagen
nucleosid
analog
varieti
target
broadspectrum
antivir
must
interact
although
rdrp
predict
conserv
right
hand
structur
consist
palm
thumb
finger
domain
precis
substrat
specif
polymeras
differ
viru
famili
may
vari
import
note
retrovirus
target
enzym
applic
ribonucleosid
analog
host
rna
polymeras
ii
host
enzym
target
approach
greatli
hinder
develop
retrovirus
resist
class
compound
lofti
goal
develop
mutagen
nucleosid
act
substrat
virusencod
polymeras
substrat
cellular
polymeras
prove
challeng
specif
structurefunct
relationship
defin
substrat
specif
enzym
still
larg
mysteri
recent
work
nucleosid
analog
may
provid
first
step
direct
analog
appear
incorpor
hcv
rdrp
appear
act
chain
termin
experiment
demonstr
nucleosid
analog
inhibitor
hcv
rdrp
vitro
vivo
case
mutat
confer
resist
discov
rdrp
resist
direct
toward
specif
importantli
appear
nucleosid
analog
incorpor
cellular
dnadepend
dna
polymeras
dnadepend
rna
polymeras
result
minim
cellular
toxic
concentr
effect
viru
inhibit
intracellular
phosphoryl
appear
rate
limit
promis
experi
indic
modif
pentos
ring
nucleosid
may
allow
antivir
activ
retain
reduc
cytotox
host
cell
although
differ
substrat
select
variou
polymeras
may
render
modif
viral
specif
import
note
howev
time
abil
mitochondri
transcript
machineri
impact
analog
address
often
assum
applic
mutagen
would
unlik
increas
frequenc
resist
viru
variant
would
aris
due
fact
rna
viru
error
rate
alreadi
extrem
high
approxim
one
mutat
per
genom
per
replic
cycl
bull
sanjuan
wilk
make
note
relev
paramet
difficult
measur
ultim
result
increas
mutat
frequenc
definit
known
accur
measur
avail
rna
virus
may
actual
replic
suboptim
error
rate
thu
may
possibl
exposur
viru
popul
drug
increas
mutat
rate
replic
may
allow
popul
access
peak
fit
landscap
unattain
without
treatment
may
allow
resist
mutagen
drug
target
anoth
viral
process
coadminist
mutagen
report
increas
robust
viral
subvir
pathogen
exposur
mutagen
although
other
report
select
robust
lcmv
cell
cultur
clinic
treatment
lethal
mutagen
may
unlik
gener
resist
variant
high
error
rate
rna
virus
necessari
viabil
pathogenesi
host
like
mechan
resist
select
higherfidel
polymeras
would
restrict
quasispeci
divers
counter
exogen
increas
mutat
rate
surprisingli
ribavirinresist
variant
pv
identifi
wherebi
resist
mediat
increas
polymeras
fidel
approxim
threefold
importantli
although
two
separ
research
group
abl
isol
ribavirinresist
pv
variant
isol
exactli
mutat
suggest
may
limit
number
resist
mechan
counter
continu
exposur
mutagen
interestingli
mutat
occur
locat
enzym
remot
catalyt
site
subsequ
work
resist
variant
demonstr
restrict
tropism
lessen
pathogenesi
mammalian
host
suggest
error
rate
tightli
regul
viru
popul
maintain
optim
level
quasispeci
divers
thu
even
lethal
mutagen
unabl
complet
extinguish
viru
popul
chang
error
frequenc
slightli
may
suffici
least
prevent
diseas
viru
spread
furthermor
applic
mutagen
combin
tradit
viral
inhibitor
may
allow
extinct
viru
popul
condit
either
treatment
alon
insuffici
may
inhibit
evolut
resist
howev
recent
discoveri
ribavirinresist
fmdv
polymeras
variant
indic
anoth
potenti
mechan
resist
lethal
mutagen
beyond
global
increas
polymeras
fidel
polymeras
incorpor
rmp
less
effici
wildtyp
polymeras
although
quasispeci
divers
restrict
biochem
evalu
polymeras
reveal
polymeras
lower
fidel
wildtyp
specif
discrimin
ribavirin
util
aria
et
al
submit
manuscript
thu
fmdv
attain
resist
decreas
effici
ribavirin
incorpor
although
result
tradeoff
fidel
normal
nucleotid
incorpor
specif
higher
frequenc
gmp
misincorpor
interestingli
first
mutat
phenotyp
identifi
rna
viru
demonstr
multipl
mechan
exist
confer
resist
lethal
mutagen
underscor
import
tightlycontrol
mutat
rate
rna
viru
popul
work
describ
indic
chang
viru
fidel
affect
viru
fit
pathogenesi
tropism
modul
fidel
fold
either
direct
suffici
signific
biolog
effect
whether
descent
extinct
catastroph
quasispeci
restrict
result
attenu
discoveri
ribavirinresist
mutat
remot
activ
site
pv
suggest
mutat
polymeras
activ
site
sole
mechan
modul
fidel
chang
overal
enzym
conform
dynam
may
perturb
activ
site
enough
affect
nucleotid
incorpor
kinet
thu
fidel
target
viral
polymeras
small
molecul
drug
could
possibl
affect
conform
dynam
requir
fidel
viral
replic
thu
creat
antivir
effect
howev
interact
necessari
elicit
effect
unknown
complic
design
drug
furthermor
highthroughput
screen
approach
identifi
small
molecul
modul
small
chang
fidel
technic
challeng
addit
limit
might
requir
complet
distinct
molecul
target
individu
viru
polymeras
owe
differ
enzym
structur
activ
thu
broad
applic
drug
may
sever
limit
interest
potenti
applic
highfidel
viral
variant
attenu
vaccin
strain
investig
ribavirin
resist
pv
variant
indic
demonstr
reduc
tissu
tropism
pathogen
confer
protect
immun
wildtyp
pv
infect
mous
model
may
provid
broadli
applic
strategi
engin
liveattenu
vaccin
rna
virus
rna
virus
gener
experi
heavi
fit
loss
expos
mutagen
toler
rna
virus
mutagen
may
vari
virus
even
close
relat
demonstr
sensit
ribavirin
treatment
close
relat
picornaviru
pv
surprisingli
due
increas
frequenc
ribavirin
incorpor
util
ribavirin
less
effici
pv
vitro
primer
extens
assay
graci
jd
et
al
manuscript
prepar
instead
appear
constrain
lower
extinct
threshold
equival
number
mutat
caus
deleteri
fit
effect
genom
pv
genom
graci
jd
et
al
manuscript
prepar
indic
virus
may
suscept
lethal
mutagenesisbas
antivir
approach
owe
differ
mutat
robust
possibl
due
constraint
primari
protein
code
sequenc
rna
structur
element
limit
toler
mutat
measur
toler
organ
genet
chang
ratio
nonsynonym
synonym
mutat
dnd
nonsynonym
mutat
indic
chang
codon
particular
amino
acid
wherea
synonym
mutat
indic
chang
primari
nucleotid
sequenc
chang
protein
code
function
owe
degeneraci
genet
code
thu
dnd
ratio
consid
measur
select
pressur
virus
exhibit
low
dnd
ratio
may
therefor
display
increas
sensit
lethal
mutagenesi
genom
conserv
therefor
may
demonstr
reduc
mutat
robust
virus
replic
heighten
select
pressur
may
therefor
opportun
target
mutagenesisbas
antivir
approach
despit
extens
investig
antivir
lethal
mutagen
vitro
attempt
exploit
theori
clinic
use
begin
although
ribavirin
shown
potent
mutagen
rna
virus
vitro
inform
regard
clinic
import
mechan
action
clinic
ribavirin
therapi
limit
controversi
regard
clinic
trial
new
antivir
mutagen
provid
critic
insight
translat
vitro
observ
therapeut
use
well
provid
new
avenu
drug
develop
number
nucleosid
analog
particularli
exhibit
ambigu
base
pair
properti
shown
suffici
mutagen
potent
antivir
vitro
pharmacolog
toxicolog
liabil
remain
thu
research
lead
improv
select
pharmacolog
properti
requir
understand
substrat
specif
host
cell
kinas
ribonucleotid
reductas
still
infanc
field
profound
implic
design
futur
antivir
nucleosid
research
area
like
provid
novel
direct
improv
select
pharmacokinet
pharmacodynam
nucleosid
analog
furthermor
attempt
studi
implic
lethal
mutagenesi
clinic
set
undertaken
emerg
viral
resist
host
cell
genotox
effect
cellular
metabol
process
undesir
offtarget
interact
complic
translat
lethal
mutagenesi
clinic
clearli
number
high
regulatori
hurdl
clear
highlymutagen
nucleosid
analog
approv
use
patient
regard
pioneer
effort
koroni
pharmaceut
move
stealth
nucleosid
clinic
inform
worth
watch
come
year
subject
like
see
rapid
advanc
viral
resist
mutagen
often
assum
primari
mechan
resist
lethal
mutagen
would
overal
increas
polymeras
fidel
prove
true
case
pv
howev
fmdv
ribavirin
resist
mutat
identifi
sierra
et
al
demonstr
resist
mechan
possibl
polymeras
discrimin
specif
nucleotid
investig
pv
fmdv
ribavirinresist
virus
indic
viral
mutat
rate
tightli
control
like
evolutionarili
optim
thu
understand
interplay
viral
fit
polymeras
fidel
like
import
implic
develop
antivir
drug
well
gener
effect
vaccin
natur
rna
viru
replic
result
gener
approxim
one
mutat
per
genom
high
mutat
frequenc
result
gener
viral
quasispeci
extens
genet
divers
extinct
threshold
viral
popul
depend
upon
mutat
rate
fecund
virus
may
evolv
increas
mutat
robust
counter
neg
effect
high
error
rate
antivir
strategi
base
increas
viral
mutat
rate
lethal
mutagenesi
may
allow
effect
viral
inhibit
n
minim
potenti
gener
resist
antivir
nucleosid
ribavirin
decreas
viru
viabil
vitro
increas
viral
mutat
frequenc
although
clinic
import
mutagenesi
still
unresolv
chemic
modifici
ribavirin
fail
produc
potent
mutagen
yet
univers
nonhydrogenbond
nucleosid
shown
limit
capac
act
viral
mutagen
vitro
mani
promiscu
nucleosid
analog
shown
potent
induct
viral
mutat
vitro
favor
biochem
properti
although
one
advanc
clinic
lethal
mutagen
design
potent
antivir
lethal
mutagen
requir
optim
structur
characterist
influenc
interact
viral
polymeras
well
host
cell
metabol
enzym
polioviru
gener
resist
ribavirin
evolv
higherfidel
polymeras
footandmouth
diseas
viru
variant
display
resist
ribavirin
treatment
specif
discrimin
ribavirin
maintain
quasispeci
divers
reduc
polymeras
fidel
closelyrel
virus
may
differ
significantli
suscept
lethal
mutagenesi
owe
variat
toler
error
threshold
treatment
nucleosid
mutagen
increas
number
mutat
per
genom
decreas
fit
progeni
viral
popul
repres
mono
diand
triphosphoryl
form
nucleosid
respect
rdrp
rnadepend
rna
polymeras
